Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2017
Dec. 31, 2016
Current assets:    
Cash $ 1,590,081 $ 199,929
Advances on research and development contract services, including $181,510 made to or through Theradex at December 31, 2016 183,490
Prepaid expenses and other current assets 60,798 49,992
Total current assets 1,650,879 433,411
Total assets 1,650,879 433,411
Current liabilities:    
Accounts payable and accrued expenses 163,184 159,595
Research and development contract liabilities, including $37,589 and $33,216 to Theradex at September 30, 2017 and December 31, 2016, respectively 93,029 59,056
Total current liabilities 256,213 218,651
Commitments and contingencies
Stockholders' equity:    
Preferred Stock, $0.0001 par value; authorized - 10,000,000 shares; issued and outstanding - 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, $50.00 per share redemption value; aggregate redemption value - $17,500,000; liquidation preference based on assumed conversion into common shares - 4,375,000 shares 3,500,000 3,500,000
Common stock, $0.0001 par value; authorized - 100,000,000 shares; issued and outstanding - 58,025,814 shares and 47,875,814 shares at September 30, 2017 and December 31, 2016, respectively 5,802 4,787
Additional paid-in capital 19,971,660 17,416,974
Accumulated deficit (22,082,796) (20,707,001)
Total stockholders' equity 1,394,666 214,760
Total liabilities and stockholders' equity $ 1,650,879 $ 433,411